Table 1.

Active clinical trials targeting CAF in lung cancer and PDAC.

Lung Cancer
Goal	Compound	Class	ID	Title	Phase	Status
Reduce ECM and IL-1β	Canakinumab	mAB targeting IL-1β	NCT03447769	Canakinumab as Adjuvant Therapy in Adult Subjects with Stages AJCC/UICC v. 8 II-IIIA and IIIB (T > 5 cm N2) Completely Resected NSCLC	Phase III	Recruiting
Prevent activation of CAFs and block CAF secretome	Erdafitinib	TKI of FGF receptor 1-4	NCT02699606	Erdafitinib, A Pan- FGFR Tyrosine Kinase Inhibitor, In Asian Participants with Advanced NSCLC, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma	Phase II	Active, not recruiting
Prevent generation and activation of CAFs	Entinostat	HDAC inhibitor	NCT02437136	Entinostat with Pembrolizumab in NSCLC with Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer	Phase II	Active recruiting
			NCT01928576	Epigenetic Therapy with Azacitidine and Entinostat with Concurrent Nivolumab in Subjects With Metastatic NSCLC	Phase II	Recruiting
Prevent generation and activation of CAFs	Vorinstat	HDAC inhibitor	NCT02638090	Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC	Phase I/II	Active recruiting
Prevent generation and activation of CAFs	Mocetinostat	HDAC inhibitor	NCT02805660	Mocetinostat and Durvalumab in Patients with Advanced Solid Tumors and NSCLC	Phase II	Completed, no results yet
PDAC
Goal	Compound	Class	ID	Title	Phase	Status
Reduce ECM and IL-1β	Canakinumab	mAB targeting IL-1β	NCT04581343	A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1)	Phase Ib	Recruiting
Reduce ECM and TGF-β	Losartan	Angiotensin II receptor antagonist	NCT03563248	Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer	Phase II	Active recruiting
			NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	Phase II	Active not recruiting
Normalize CAFs	ATRA	Vitamin A derivative	NCT04241276	Phase IIb Randomized Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (STARPAC2)	Phase IIb	Not yet recruiting
Normalize CAFs	Paricalcitol	Vitamin D analogue	NCT03520790	Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer	Phase I/II	Active, not recruiting
Reduce CAF secretome	Plerixafor	CXCR4 antagonist	NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Phase II	Recruiting
Reduce CAF secretome	GSK2256098	FAK inhibitor	NCT02428270	A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	Phase II	Active, not recruiting
Target FAP+ CAFs	BXCL701 (talabostat)	Small molecule inhibitor of FAP and dipeptidyl peptidases	NCT04123574	A Pilot Study of BXCL701 in Patients With Pancreatic Cancer	Early phase I	Recruiting
Target FAP+ CAFs	CAR-T targeting nectin4/FAP	CAR-T cell	NCT03932565	Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors	Phase I	Recruiting